197 related articles for article (PubMed ID: 37326764)
1. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
[TBL] [Abstract][Full Text] [Related]
2. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
Rillamas-Sun E; Kwan ML; Carlos C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
Res Sq; 2023 Mar; ():. PubMed ID: 36993531
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Disease After Aromatase Inhibitor Use.
Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
[TBL] [Abstract][Full Text] [Related]
4. Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data.
Choi SH; Kim KE; Park Y; Ju YW; Jung JG; Lee ES; Lee HB; Han W; Noh DY; Yoon HJ; Moon HG
Breast; 2020 Dec; 54():25-30. PubMed ID: 32890789
[TBL] [Abstract][Full Text] [Related]
5. Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Gupta T; Purington N; Liu M; Han S; Sledge G; Schapira L; Kurian AW
Breast Cancer Res Treat; 2022 Nov; 196(1):175-183. PubMed ID: 36030472
[TBL] [Abstract][Full Text] [Related]
6. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant aromatase inhibitor therapy and early markers for cardiovascular disease in breast cancer survivors.
van Ommen-Nijhof A; Jacobse JN; Steggink LC; Lefrandt JD; Gietema JA; van Leeuwen FE; Schaapveld M; Sonke GS
Breast Cancer Res Treat; 2022 Dec; 196(3):591-602. PubMed ID: 36181605
[TBL] [Abstract][Full Text] [Related]
10. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.
Kwan ML; Lo JC; Laurent CA; Roh JM; Tang L; Ambrosone CB; Kushi LH; Quesenberry CP; Yao S
J Cancer Surviv; 2023 Feb; 17(1):139-149. PubMed ID: 33565036
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors and the incidence of Parkinson disease: A population-based cohort study.
Khosrow-Khavar F; Azoulay L; Montastruc JL; Montastruc F; Renoux C
Cancer; 2022 Jun; 128(12):2339-2347. PubMed ID: 35363379
[TBL] [Abstract][Full Text] [Related]
15. Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.
Kwan ML; Cheng RK; Iribarren C; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Shen H; Rillamas-Sun E; Santiago-Torres M; Hershman DL; Kushi LH; Greenlee H
J Clin Oncol; 2022 May; 40(15):1635-1646. PubMed ID: 35025627
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
Hamood R; Hamood H; Merhasin I; Keinan-Boker L
Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
[TBL] [Abstract][Full Text] [Related]
17. Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea.
Kim JE; Choi J; Park J; Han W; Kang D; Choi JY
J Am Heart Assoc; 2022 Oct; 11(20):e026743. PubMed ID: 36250658
[TBL] [Abstract][Full Text] [Related]
18. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.
Khosrow-Khavar F; Yin H; Barkun A; Bouganim N; Azoulay L
Ann Oncol; 2018 Mar; 29(3):744-748. PubMed ID: 29293897
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
